Core Viewpoint - The article emphasizes the importance of selecting the appropriate expression host for recombinant protein production, as it significantly impacts yield, post-translational modifications, and functional activity [1]. Group 1: Expression Systems Overview - Recombinant proteins are widely used in life sciences, biopharmaceuticals, vaccine development, and in vitro diagnostics [1]. - Mainstream expression systems include E. coli, mammalian cells, yeast, and insect cells, each with distinct advantages and limitations [1]. - E. coli is favored for its rapid growth, low cost, and high yield, but lacks a complete post-translational modification system and faces challenges with inclusion body refolding [1]. - Mammalian cells (e.g., CHO, HEK293) produce proteins closer to their natural state, essential for therapeutic protein production, but have lower yields and more complex operations [1]. - Yeast and insect cells offer unique advantages in cost control, large-scale production, and complex protein folding, but their post-translational modifications differ from those in mammals [1]. Group 2: Lecture Details - The upcoming lecture will focus on strategies for selecting protein expression systems, featuring Dr. Yu Lulu, a senior R&D manager at Yiqiao Shenzhou [2][4]. - The lecture will analyze the characteristics and application scenarios of various expression systems, discussing how to choose the right host based on the target protein's research background, physicochemical properties, biological functions, and downstream applications [2]. - It will also address common issues in protein expression and share practical experiences for obtaining high-quality recombinant proteins [2][6]. Group 3: Speaker Background - Dr. Yu Lulu holds a Ph.D. in Biochemistry and Molecular Biology from Peking University and has extensive experience in evaluating, designing, and optimizing CRO projects in recombinant protein expression and purification [5].

Core Viewpoint - The article emphasizes the importance of selecting the appropriate expression host for recombinant protein production, as it significantly impacts yield, post-translational modifications, and functional activity [1]. Group 1: Expression Systems Overview - Recombinant proteins are widely used in life sciences, biopharmaceuticals, vaccine development, and in vitro diagnostics [1]. - Current mainstream expression systems include E. coli, mammalian cells, yeast, and insect cells, each with its own advantages and limitations [1]. - E. coli is favored for its rapid growth, low cost, and high yield, but lacks a complete post-translational modification system and faces challenges with inclusion body refolding [1]. - Mammalian cells (e.g., CHO, HEK293) produce proteins closer to their natural state, essential for therapeutic protein production, but have lower yields and more complex operations [1]. - Yeast and insect cells offer unique advantages in cost control, large-scale production, and complex protein folding, but their post-translational modifications differ from those in mammals [1]. Group 2: Expression Host Selection Strategy - The selection of an expression host should be based on a multidimensional evaluation system considering the target protein's research background, physicochemical properties, biological functions, and downstream applications [1][2]. - The upcoming lecture will focus on strategies for selecting protein expression systems, analyzing the characteristics and application scenarios of various commonly used systems, and discussing real-world cases [2][7]. Group 3: Speaker and Event Details - The lecture will be presented by Dr. Yulu Lu, a senior R&D manager at Beijing Yiqiao Shenzhou Technology Co., Ltd., who has extensive experience in evaluating, designing, and optimizing CRO projects in recombinant protein expression and purification [4][5][6]. - The event is scheduled for May 15 at 19:00, and will address common issues in protein expression and share practical experiences for obtaining high-quality recombinant proteins [3][7].